Skip to Content

UK Edition. Click here for US version.

CAPECITABINE MYLAN 150 MG FILM-COATED TABLETS

Active substance(s): CAPECITABINE

View full screen / Print PDF » Download PDF ⇩
Transcript
Package leaflet: Information for the patient
Capecitabine 150 mg film-coated tablets
capecitabine
Read all of this leaflet carefully before you start taking this medicine because it contains
important information for you.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to others. It may
harm them, even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This includes any possible
side effects not listed in this leaflet. See section 4.

What is in this leaflet
1.
What Capecitabine is and what it is used for
2.
What you need to know before you take Capecitabine
3.
How to take Capecitabine
4.
Possible side effects
5.
How to store Capecitabine
6.
Contents of the pack and other information

1. What Capecitabine is and what it is used for
Capecitabine belongs to the group of medicines called "cytostatic medicines", which stop the
growth of cancer cells. Capecitabine film-coated tablets contain 150 mg capecitabine, which
itself is not a cytostatic medicine. Only after being absorbed by the body is it changed into an
active anti-cancer medicine (more in tumour tissue than in normal tissue).
Capecitabine is used in the treatment of colon, rectal, gastric, or breast cancers.
Furthermore, Capecitabine is used to prevent new occurrence of colon cancer after complete
removal of the tumour by surgery.
Capecitabine may be used either alone or in combination with other medicines.

2.

What you need to know before you take Capecitabine

Do not take Capecitabine:

if you are allergic to capecitabine or any of the other ingredients of this medicine (listed
in section 6). You must inform your doctor if you know that you have an allergy or
over-reaction to this medicine,

if you previously have had severe reactions to fluoropyrimidine therapy (a group of
anticancer medicines such as fluorouracil),

if you are pregnant or nursing,

if you have severely low levels of white cells or platelets in the blood (leucopenia,
neutropenia or thrombocytopenia),

if you have severe liver or kidney problems,

if you have a known deficiency for the enzyme dihydropyrimidine dehydrogenase
(DPD) involved in the metabolism of uracil and thymine, or



if you are being treated now or have been treated in the last 4 weeks with brivudine,
sorivudine or similar classes of substance as part of herpes zoster (chickenpox or
shingles) therapy.

Warnings and precautions
Talk to your doctor or pharmacist before taking Capecitabine

if you have liver or kidney diseases

if you have or had heart problems (for example an irregular heartbeat or pains to the
chest jaw and back brought on by physical effort and due to problems with the blood
flow to the heart)

if you have brain diseases (for example, cancer that has spread to the brain, or nerve
damage (neuropathy))

if you have calcium imbalances (seen in blood tests)

if you have diabetes

if you cannot keep food or water in your body because of severe nausea and vomiting

if you have diarrhoea

if you are or become dehydrated

if you have imbalances of ions in your blood (electrolyte imbalances, seen in tests)

if you have a history of eye problems as you may need extra monitoring of your eyes

if you have a severe skin reaction.
DPD deficiency: DPD deficiency is a rare condition present at birth that is not usually
associated with health problems unless you receive certain medicines. If you have an
unrecognised DPD deficiency and take capecitabine, you may experience severe forms of the
side effects listed under section 4 ‘Possible side effects’. Contact your doctor immediately if
you are concerned about any of the side effects or if you notice any additional side effects not
listed in the leaflet (see section 4 ‘Possible side effects’).
Children and adolescents
Capecitabine is not indicated in children and adolescents. Do not give Capecitabine to
children and adolescents.
Other medicines and Capecitabine
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other
medicines. This is extremely important, as taking more than one medicine at the same time
can strengthen or weaken the effect of the medicines.
You need to be particularly careful if you are taking any of the following:

gout medicines (allopurinol),

blood-thinning medicines (coumarin, warfarin),

certain anti-viral medicines (sorivudine and brivudine),

medicines for seizures or tremors (phenytoin),

interferon alpha radiotherapyand certain medicines used to treat cancer (folinic acid,
oxaliplatin, bevacizumab, cisplatin, irinotecan),

medicines used to treat folic acid deficiency.
Capecitabine with food
You should take Capecitabine no later than 30 minutes after meals (see section 3 below).
Pregnancy and breast-feeding
Before starting treatment, you must tell your doctor if you are pregnant, if you think you are
pregnant or if you intend to become pregnant. You must not take Capecitabine if you are
pregnant or think you might be. You must not breast-feed if you are taking Capecitabine.

Ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Capecitabine may make you feel dizzy, nauseous or tired. It is therefore possible that
Capecitabine could affect your ability to drive a car or operate machinery.
3.

How to take Capecitabine

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your
doctor or pharmacist if you are not sure.
Capecitabine should only be prescribed by a doctor experienced in the use of anticancer
medicines.
Capecitabine tablets should be swallowed whole with water and within 30 minutes of a
meal.
Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of
Capecitabine is based on your body surface area. This is calculated from your height and
weight. The recommended dose for adults is 1250 mg/m2 of body surface area taken two
times daily (morning and evening). Two examples are provided here: A person whose body
weight is 64 kg and height is 1.64 m has a body surface area of 1.7 m2 and should take 4
tablets of 500 mg and 1 tablet of 150 mg two times daily. A person whose body weight is
80 kg and height is 1.80 m has a body surface area of 2.00 m2 and should take 5 tablets of
500 mg two times daily.
Capecitabine tablets are usually taken for 14 days followed by a 7 day rest period (when no
tablets are taken). This 21 day period is one treatment cycle.
In combination with other medicines the recommended dose for adults may be less than
1250 mg/m2 of body surface area, and you may need to take the tablets over a different time
period (e.g. every day, with no rest period).
Your doctor will tell you what dose you need to take, when to take it and for how long you
need to take it.
Your doctor may want you to take a combination of 150 mg and 500 mg tablets for each dose.

Take the tablets morning and evening as prescribed by your doctor.

Take the tablets within 30 minutes after the end of a meal (breakfast and dinner).

It is important that you take all your medicine as prescribed by your doctor.
If you take more Capecitabine than you should
If you take more Capecitabine than you should, contact your doctor as soon as possible before
taking the next dose.
You might get the following side effects if you take a lot more capecitabine than you should:
feeling or being sick, diarrhoea, inflammation or ulceration of the gut or mouth, pain or
bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds
of blood cells). Tell your doctor immediately if you experience any of these symptoms.
If you forget to take Capecitabine
Do not take a double dose to make up for a forgotten dose. Instead, continue your regular
dosing schedule and check with your doctor.

If you stop taking Capecitabine
There are no side effects caused by stopping treatment with capecitabine. In case you are
using coumarin anticoagulants (containing e.g. phenprocoumon), stopping capecitabine might
require that your doctor adjusts your anticoagulant dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
STOP taking Capecitabine immediately and contact your doctor if any of these symptoms
occur:

Diarrhoea: if you have an increase of 4 or more bowel movements compared to your
normal bowel movements each day or any diarrhoea at night.

Vomiting: if you vomit more than once in a 24-hour time period.

Nausea: if you lose your appetite, and the amount of food you eat each day is much
less than usual.

Stomatitis: if you have pain, redness, swelling or sores in your mouth and/or throat.

Hand-and-foot skin-reaction: if you have pain, swelling, redness or tingling of hands
and/or feet.

Fever: if you have a temperature of 38°C or greater.

Infection: if you experience signs of infection caused by bacteria, viruses or other
organisms.

Chest pain: if you experience pain localised to the centre of the chest, especially if it
occurs during exercise.

Steven-Johnson syndrome: if you experience painful red or purplish rash that spreads
and blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth
and lips), in particular if you had before light sensitivity, infections of the respiratory
system (e.g. bronchitis) and/or fever.
If caught early, these side effects usually improve within 2 to 3 days after treatment
discontinuation. If these side effects continue, however, contact your doctor immediately.
Your doctor may instruct you to restart treatment at a lower dose.
In addition to the above, when Capecitabine is used alone, very common side effects, which
may affect more than 1 person in 10 are:

abdominal pain

rash, dry or itchy skin

tiredness

loss of appetite (anorexia).
These side effects can become severe; therefore, it is important that you always contact your
doctor immediately when you start to experience a side effect. Your doctor may instruct you
to decrease the dose and/or temporarily discontinue treatment with Capecitabine Mylan. This
will help reduce the likelihood that the side effect continues or becomes severe.
Other side effects are:
Common side effects (may affect up to 1 in 10 people) include:

decrease in the number of white blood cells or red blood cells (seen in tests)

dehydration, weight loss

sleeplessness (insomnia), depression













headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling
sensation), taste changes
eye irritation, increased tears, eye redness (conjunctivitis)
inflammation of the veins (thrombophlebitis)
shortness of breath, nose bleeds, cough, runny nose
cold sores or other herpes infections
infections of the lungs or respiratory system (e.g. pneumonia or bronchitis)
bleeding from the gut, constipation, pain in upper abdomen, indigestion, excess wind,
dry mouth
skin rash, hair loss (alopecia), skin reddening, dry skin, itching (pruritus), skin
discolouration, skin loss, skin inflammation, nail disorder
pain in the joints, or in the limbs (extremities), chest or back
fever, swelling in the limbs, feeling ill
problems with liver function (seen in blood tests) and increased blood bilirubin
(excreted by the liver).

Uncommon side effects (may affect up to 1 in 100 people) include:

blood infection, urinary tract infection, infection of the skin, infections in the nose and
throat, fungal infections (including those of the mouth), influenza, gastroenteritis, tooth
abscess

lumps under the skin (lipoma)

decrease in blood cells including platelets, thinning of blood (seen in tests)

allergy

diabetes

decrease in blood potassium, malnutrition, increased blood triglycerides

confusional state, panic attacks, depressed mood, decreased libido

difficulty speaking, impaired memory, loss of movement coordination, balance
disorder, fainting, nerve damage (neuropathy) and problems with sensation

blurred or double vision

vertigo, ear pain

irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack
(infarction)

blood clots in the deep veins, high or low blood pressure, hot flushes, cold limbs
(extremities) purple spots on the skin

blood clots in the veins in the lung (pulmonary embolism), collapsed lung, coughing up
blood

asthma, shortness of breath on exertion

bowel obstruction, collection of fluid in the abdomen, inflammation of the small or large
intestine, the stomach or the oesophagus, pain in the lower abdomen, abdominal
discomfort, heartburn (reflux of food from the stomach), blood in the stool

jaundice (yellowing of skin and eyes)

skin ulcer and blister, reaction of the skin with sunlight, reddening of palms, swelling
or pain of the face

joint swelling or stiffness, bone pain, muscle weakness or stiffness

fluid collection in the kidneys, increased frequency of urination during the night,
incontinence, blood in the urine, increase in blood creatinine (sign of kidney
dysfunction)

unusual bleeding from the vagina

swelling (oedema), chills and rigors.
Some of these side effects are more common when capecitabine is used with other medicines
for the treatment of cancer. Other side-effects seen in this setting are the following:

Common side effects (may affect up to 1 in 10 people) include:

decrease in blood sodium, magnesium or calcium, increase in blood sugar

nerve pain

ringing or buzzing in the ears (tinnitus), loss of hearing

vein inflammation

hiccups, change in voice

pain or altered/abnormal sensation in the mouth, pain in the jaw

sweating, night sweats

muscle spasm

difficulty in urination, blood or protein in the urine

bruising or reaction at the injection site (caused by medicines given by injection at the
same time).
Rare side effects (may affect up to 1 in 1,000 people) include:

narrowing or blockage of tear duct (lacrimal duct stenosis)

liver failure

inflammation leading to dysfunction or obstruction in bile secretion (cholestatic
hepatitis)

specific changes in the electrocardiogram (QT prolongation)

certain types of arrhythmia (including ventricular fibrillation, torsade de pointes, and
bradycardia)

eye inflammation causing eye pain and possibly eyesight problems

inflammation of the skin causing red scaly patches due to an immune system illness.
Very rare side effects (may affect up to 1 in 10,000 people) include:

severe skin reaction such as skin rash, ulceration and blistering which may
involve ulcers of the mouth, nose, genitalia, hands, feet and eyes (red and swollen
eyes).
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side
effects not listed in this leaflet. You can also report side effects directly via the Yellow Card
Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide
more information on the safety of this medicine.

5.

How to store Capecitabine

Keep this medicine out of the sight and reach of children.
Do not store above 30°C.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The
expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist
how to throw away medicines you no longer use. These measures will help protect the
environment.

6.

Contents of the pack and other information

What Capecitabine contains

The active substance is capecitabine. Each film-coated tablet contains 150 mg capecitabine.
The other ingredients are:
Tablet core: Croscarmellose sodium, microcrystalline cellulose, hypromellose, silica,
colloidal anhydrous, magnesium stearate,
Tablet coating: Hypromellose, titanium dioxide (E171), talc, macrogol 400, red iron
oxide (E172), yellow iron oxide (E172)
What Capecitabine looks like and contents of the pack
Light-peach, oval, film-coated tablets marked with ‘150’ on one side, of approximate
dimensions 11.4 mm x 5.9 mm.
Capecitabine 150 mg film-coated tablets are available in different pack sizes:
Blister packs of 60 film-coated tablets.
Unit dose blister packs of 60x1 film-coated tablets.
Not all pack sizes/types may be marketed.
Marketing Authorisation Holder
Mylan, Potters Bar, Hertfordshire, EN6 1TL, UK.
Manufacturer
Remedica Ltd., Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus.

This leaflet was last revised in 11/2015

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide